221 related articles for article (PubMed ID: 7745698)
21. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
Kozal MJ; Kroodsma K; Winters MA; Shafer RW; Efron B; Katzenstein DA; Merigan TC
Ann Intern Med; 1994 Aug; 121(4):263-8. PubMed ID: 7518658
[TBL] [Abstract][Full Text] [Related]
22. Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
Holodniy M; Katzenstein D; Mole L; Winters M; Merigan T
J Infect Dis; 1996 Oct; 174(4):854-7. PubMed ID: 8843229
[TBL] [Abstract][Full Text] [Related]
23. Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients.
Cleland A; Watson HG; Robertson P; Ludlam CA; Brown AJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):6-18. PubMed ID: 8624762
[TBL] [Abstract][Full Text] [Related]
24. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.
Novitsky V; Wester CW; DeGruttola V; Bussmann H; Gaseitsiwe S; Thomas A; Moyo S; Musonda R; Van Widenfelt E; Marlink RG; Essex M
AIDS Res Hum Retroviruses; 2007 Jul; 23(7):868-78. PubMed ID: 17678469
[TBL] [Abstract][Full Text] [Related]
25. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
Mayers D; Bethel J; Wainberg MA; Weislow O; Schnittman S
J Infect Dis; 1998 Jun; 177(6):1730-3. PubMed ID: 9607859
[TBL] [Abstract][Full Text] [Related]
26. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
[TBL] [Abstract][Full Text] [Related]
27. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.
Demeter LM; Nawaz T; Morse G; Dolin R; Dexter A; Gerondelis P; Reichman RC
J Infect Dis; 1995 Dec; 172(6):1480-5. PubMed ID: 7594706
[TBL] [Abstract][Full Text] [Related]
28. An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.
Capdepont S; Aurillac-Lavignolle V; Faure M; Dupon M; Morlat P; Ragnaud JM; Chêne G; Fleury H; Masquelier B;
J Clin Virol; 2006 May; 36(1):36-42. PubMed ID: 16513416
[TBL] [Abstract][Full Text] [Related]
29. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
[TBL] [Abstract][Full Text] [Related]
30. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
Katzenstein DA; Hammer SM; Hughes MD; Gundacker H; Jackson JB; Fiscus S; Rasheed S; Elbeik T; Reichman R; Japour A; Merigan TC; Hirsch MS
N Engl J Med; 1996 Oct; 335(15):1091-8. PubMed ID: 8813039
[TBL] [Abstract][Full Text] [Related]
31. Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment.
Zazzi M; Catucci M; De Milito A; Romano L; Venturi G; Almi P; Gonnelli A; Rubino M; Valensin PE
Infection; 1996; 24(6):419-25. PubMed ID: 9007588
[TBL] [Abstract][Full Text] [Related]
32. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine.
Frenkel LM; Wagner LE; Atwood SM; Cummins TJ; Dewhurst S
J Clin Microbiol; 1995 Feb; 33(2):342-7. PubMed ID: 7714190
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
[TBL] [Abstract][Full Text] [Related]
34. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.
Race E; Gilbert SM; Sheldon JG; Rose JS; Moffatt AR; Sitbon G; Dissanayeke SR; Cammack N; Duncan IB
AIDS; 1998 Aug; 12(12):1465-74. PubMed ID: 9727567
[TBL] [Abstract][Full Text] [Related]
35. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy.
Günthard HF; Wong JK; Ignacio CC; Guatelli JC; Riggs NL; Havlir DV; Richman DD
J Virol; 1998 Mar; 72(3):2422-8. PubMed ID: 9499103
[TBL] [Abstract][Full Text] [Related]
36. A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.
Qari SH; Winters M; Vandamme AM; Merigan T; Heneine W
Antivir Ther; 2002 Jun; 7(2):131-9. PubMed ID: 12212925
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):203-8. PubMed ID: 9495218
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
40. Clinically relevant genotype interpretation of resistance to didanosine.
Marcelin AG; Flandre P; Pavie J; Schmidely N; Wirden M; Lada O; Chiche D; Molina JM; Calvez V;
Antimicrob Agents Chemother; 2005 May; 49(5):1739-44. PubMed ID: 15855490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
